Chai Discovery Raises $400M Series C as AI-Designed Antibodies Gain Big Pharma Adoption

Summary

Chai Discovery, an AI-driven drug discovery company, announced a $400 million Series C funding round led by Index Ventures with participation from Kleiner Perkins, Sequoia Capital, and Dimension, nearly tripling its valuation to $3.8 billion. The round brings total funding to approximately $630 million and signals accelerating industry adoption of AI for molecular design.

The company builds frontier AI models that predict and reprogram molecular interactions, fundamentally changing how antibodies are discovered. Rather than screening millions of potential molecules one-by-one, Chai's systems perform rapid simulations to design high-probability candidates from a quintillion possible combinations. The newly released Chai-3 model represents a significant leap, doubling success rates to approximately 35-40% for molecular interaction targets.

Concrete validation comes from landmark partnerships with pharmaceutical giants: a licensing agreement with Pfizer granting access to Chai-3 and models trained on proprietary data, plus customer agreements with Eli Lilly and Novartis. CEO Joshua Meier stated that "AI drug discovery has moved from promise to deployment," marking a critical inflection point for the sector as companies move beyond early research into real-world pharmaceutical applications.

• Company addresses massive drug discovery challenge: navigating quintillion possible antibody designs using AI simulation instead of brute-force screening
• Despite momentum, sector still faces headwinds: no AI-discovered drug approved yet, though 173+ programs in clinical development